Google TrendMAX CASTER (200+) — Moose Def. Max Caster At TNA Bound For Glory 2026
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Issues Draft Guidance" (30 stories)

Top Headline Story

FDA Issues Draft Guidance on Robotic Surgical Devices
Lead StoryIn Compliance Magazinegeneral
4d ago

FDA Issues Draft Guidance on Robotic Surgical Devices

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNN0xoZHZUZEY4RmVHUUhmRG9fOVlPcXVzZDRHUkRGWHg1SWNmY1FTZ1Uwa21iVHl0YWp3NmY5bzFlNEZzZElUcFdpTG44bUhtSS0tdFkwdEdGUVBGMkl1bVRQZ0gzOTFCbW51eU9kYWxaZUMzT0FhZ3NsSl9QSmVjN0ZXUXZ5MUhqaFHSAZIBQVVfeXFMT0NDOEpzNjNaM3VVcTBVaHhpMEY0SmhxcllNSFQ3THRKOHQza3FXVTlLc1dWNHVlXzVVT1VUTTdIMzZURkNuN2FIY3FfVi1VZlBxVUdKUGVfSHA1STJRczV6UjdtckI3TC1CMndERWJTSUNWT05FcTkzSC11bEgwVTcybDg5dnJtNUNiaWZWMFcwVWc?oc=5" target="_blank">FDA Issues Draft Guidance on Robotic Surgical Devices</a>  <font color="#6f6f6f">In Compliance Magazine</font>

Real-time search volume
200+23m ago

max caster

Moose Def. Max Caster At TNA Bound For Glory 2026

200+23m ago

prince harry family photo story

Prince Harry Reveals the Photo He Took of Archie and Lilibet That ‘Fills My Heart’

500+33m ago

kelley knockel

1 dead, multiple injured after pair of motorcycle crashes involving deer in Iowa

200+33m ago

torino vs udinese

Torino vs Udinese: Italian Serie A stats & head-to-head

Search Results for "FDA Issues Draft Guidance"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA issues draft guidance for surgical robots
MedTech Divegeneral

FDA issues draft guidance for surgical robots

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNX0o5SEpvWlgzRFg0TkhPVnNBR0U3SkZsWGM5MFF4MVVDd1VSaGg3Y05ycm1MYTFQc0hHM0djZGRjQ09ESTBsUkY5NU5RV1dpTkNfQ1VIUkZaZUFiZGxndThVMmQwZ2M1NkJ3TFg5WTczcDBZRVRmOWljcVZ1S2kxLVlhdEJkcXdlMXplNWlZcw?oc=5" target="_blank">FDA issues draft guidance for surgical robots</a>  <font color="#6f6f6f">MedTech Dive</font>

FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products
Arnold & Portergeneral

FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNQUU5NHFib0xHSFBsZkh1R2V1WEZXQ3p6YlVaclc4R09SOXVDYi1pQU9tUzYyYlJOLTNKdGJZOGViSXY4YkJJUlU1REl5bzdtelhGUWpWT0psZVhvVlIxLVRRVWRHaHVFRmp5a2pNWGV6ZTRhaGxJbjNyVGtmTTZNeEgtQ2xNRHFwWnJ0MUhja2Q3YTgtVlJRV1ZRR1Z2Um84T1d4VF9jUmhxVHIzVGwxMXFjdEU0akEzTzlCb0EwZ0pQT2dERGdETVpMMWZrZEpzRGRrNUpZa285c19YclJwc3ZLd0xQQWM?oc=5" target="_blank">FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products</a>  <font color="#6f6f6f">Arnold & Porter</font>

Food Traceability: FDA Issues Draft Enforcement Discretion Policy for Certain Small Retailers and Restaurants
FoodSafetyTechtech

Food Traceability: FDA Issues Draft Enforcement Discretion Policy for Certain Small Retailers and Restaurants

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQT19JelROQnlOd1paTkI1SzhhaFU1S2VHUkdxbDVmWmw0SmtQSWc0Wk8xLUVtR0syZ1ZoRlB1TmVLVnllY3hGc2lHUXRrdjVqcHIxMThfSHR1clBLU0p1ZU9CRUNlZGVrU2hpSUh2LWpGR1pGb0tyRHpVR0toNWhGMTY4dUF2ek1KYTFHZWx4TmUyb1BLckQxeWtHLWdTRENqZWNVa0E2Y2tJNHltQ0l0ZFBNVWdraVRacVZGZ1h5RVo1WDRwSUsyTFJjNUQzdnJzWlNvZEdvQWVZZFJIUnl3RWZSZw?oc=5" target="_blank">Food Traceability: FDA Issues Draft Enforcement Discretion Policy for Certain Small Retailers and Restaurants</a>  <font color="#6f6f6f">FoodSafetyTech</font>

FDA Issues Draft Guidance on Robotically-Assisted Surgical Devices
Medical Device and Diagnostic industrygeneral

FDA Issues Draft Guidance on Robotically-Assisted Surgical Devices

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOLTRrNVBmLWc1RTd0UUFOS1lDa2tVbFdqaUdmSjkzTER6N1VwTHVveWRkbzFTdk5BY0dCWWpzdmxVMGEwNHVpMTFVT3dUa2hDOGV3VHNJWkszQm8zc0lCRmU2WTFmSWtuRWNvSmdRV3pKeFRKakpRMEFEdEdYRGFNVFNzVHk0TjVCckg3NXZ3cVJwcmh5bXIwcHdRZll1S3gyT3lYTQ?oc=5" target="_blank">FDA Issues Draft Guidance on Robotically-Assisted Surgical Devices</a>  <font color="#6f6f6f">Medical Device and Diagnostic industry</font>

FDA Issues Draft Guidance on Payor Communications to Address Statutory Changes
Akin Gump Strauss Hauer & Feld LLPworld

FDA Issues Draft Guidance on Payor Communications to Address Statutory Changes

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPUjAwcEk1bnprOG9rbTQ4ZjVnLWsySGpFS0Jia19pSjlFY0xaOWx6ZGEtb0otam1JQ3k2YVptNjhpY0c1Q2s1RzhpSmdCbEw0aUJmMFRzdllzcUlxcUVidENULVdhZzVpSkhQXzI0ZjI1UTBSeFRNMGN1RnRaNFp1c2RvSlBNNXBRWFZEc1NyaXhmR1BQSnI1R1dkdi1ycUl5eDVmMDhqSTRkMHQwaUF6X21YZlZoSUE0SGNSbzljb0MzY29tRm5Sa1doWmE?oc=5" target="_blank">FDA Issues Draft Guidance on Payor Communications to Address Statutory Changes</a>  <font color="#6f6f6f">Akin Gump Strauss Hauer & Feld LLP</font>

FDA Issues Draft Guidance to Validate Non-Animal Testing Methods in Drug Development
Applied Clinical Trialsgeneral

FDA Issues Draft Guidance to Validate Non-Animal Testing Methods in Drug Development

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQeHBTT1pzYmxnVW5xc0p0cW52UDNWRXNKX2NQQndnLTBNdTZfMENqM2JCVkk4VlljWHZnU0FncjJPODBGWnc5SVJTNkREOVNibXNVTS1tdnF1UHhER1JoMlVMd0F1WWc3YWhreTlaRnU4NUd3dGhuZUFkMFFtaGl3WmplRWU5cC16UGJSYzd1THlVLWprY2FYV0x6cjM1Qy04NjBNQkNxY3JTNGJaUUkzbVA4SldRVWdxSlgxaQ?oc=5" target="_blank">FDA Issues Draft Guidance to Validate Non-Animal Testing Methods in Drug Development</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Exclusive: FDA issues industry-friendly gene therapy guidance
Axiosgeneral

Exclusive: FDA issues industry-friendly gene therapy guidance

<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE8zS1REd3F4bmZ4ZlU3bHpUVkFiVklva05XbEtJTkhyR2ZUeTk0ZncyNld0aGJyWW5GWE9OZVZfMHhlb3RFY09Lbnl2NVFCSU8zaTFSajFWckRmeEtRcWVRYkgxaDdCM1daOWF6RkF5MGF6Q3Jq?oc=5" target="_blank">Exclusive: FDA issues industry-friendly gene therapy guidance</a>  <font color="#6f6f6f">Axios</font>

New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
Pharmaceutical Executivegeneral

New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQcHVMN3ZmNThudmpVRktNWXNrMk5YZUpnZ0QtQnZnRHhTZVk3dnFJbW9JQ25ZdVB0ZnlNOGlZS0ZLeDFQckY0aFZLandsNWlSNllpek5JMFhNT3NFV3YxdmFQZkdLZ1FNNXZ3N3ZONWFxR3NETUdTYThGZjFDRkxmejhhSjgxbnMxYTI2cDF2S0tuNkVlUkp6YU9UVVVwMkw5T2tzeXE5bFdWdWd5R2dQR0g0ZWN5N2QtOHMyNVFYS3FKSk9l?oc=5" target="_blank">New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Policy Watch: FDA issues draft guidance on genome-editing safety
Chemical & Engineering Newsgeneral

Policy Watch: FDA issues draft guidance on genome-editing safety

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNd3lZZFJ2UGJxemt2dGZ3WXpEZm5UbWhTTEdiVHJ5LTJfNnZsaGQycFNfcm1vX2J6cEN0NUVOOHVYQndNQktzTi1xRXJpbmJ2TWR3UXJkdlFNMU9lUjJvelR3dTBrc19CR3F6SFBaWHYyaVVtTGp6eTdEWmlra3NhYU9DSzN4RklKZ3MxMHVJbEFRbTVZeVVDTXlZaEV2LUI1Q0xkQTJSWWZuUQ?oc=5" target="_blank">Policy Watch: FDA issues draft guidance on genome-editing safety</a>  <font color="#6f6f6f">Chemical & Engineering News</font>

FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies
Center for Biosimilarstech

FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYlI0d2tJU2p5cncyb1VHdWRDQ29uaVE4bzdMOE9Gd2xtenEtYmptM2FQWjQxSzllU0tkZTZzUFIxOHNtNnE4OE8wMGp5cy1Vd1FsbVFUZXh1eVUwV2ZuSlhuNDVZOTJMUF9INWpjNFBsTWpkYnhBZExnUEdrUi1VMXc0RlFDdE14R1l4QUIyc25JcFVQY3dmMnp3SFNac1ppcUdBaFJCdFpLR1l2SGJBOGhOY1Z4UWtYc2NB?oc=5" target="_blank">FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies</a>  <font color="#6f6f6f">Center for Biosimilars</font>

FDA Issues Draft Guidance on Fruit and Vegetable Juice as Color Additives in Food
www.hlc.comgeneral

FDA Issues Draft Guidance on Fruit and Vegetable Juice as Color Additives in Food

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNkdRVTFLMXhOWWdqZTB2MnhNSlF6Q2lNdUxhM3hzN19UeF8wRnk5dGc1N1ZTbWk0Uk1paEhiaE9ZUmFFNTZlM2hGWmdHdmNWYWUwXzdzQkd6V3pNUDBRenlkb2JvQ1Rmbm9nWXN2STJhQXRja2RkWWl0M0Fnblg3MVBjejVzQXFnY0VId3BKeUYtSjZiUnNRTVVMX2plb092VWptVHBoZ1JtUFNhNUFkNnRtU0ZmUDBM?oc=5" target="_blank">FDA Issues Draft Guidance on Fruit and Vegetable Juice as Color Additives in Food</a>  <font color="#6f6f6f">www.hlc.com</font>

FDA Issues Draft Guidance on Tobacco Harm Reduction Products
Citizens Against Government Wastegeneral

FDA Issues Draft Guidance on Tobacco Harm Reduction Products

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNYTVRdkVwTXZNSWJJWXlTejhIdy15N2YtZVc5TDZnVllKOFhpbkZmSldlSnVNeWNYVU85YktuTU5LSF9NWl9aVXgxcW5rWHNEYnpLQUZqekhaRDN2S2FXWFY2bEpaTnJoclZ2bmxvdUtlUndxcllSMkUzbjI1eDI1MjRORGZYODlBdkE?oc=5" target="_blank">FDA Issues Draft Guidance on Tobacco Harm Reduction Products</a>  <font color="#6f6f6f">Citizens Against Government Waste</font>

FDA Issues New Guidance for Submitting Patent Information for Listing in the “Orange Book”
JDSuprageneral

FDA Issues New Guidance for Submitting Patent Information for Listing in the “Orange Book”

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPakJsV3ZWRzAyQVoyb1lUNE01dFZGQzlIRVFxd2RiZHktU1dxUTZiTjVqWFhYaklYcWcxSHR3SlhVbFZ2Q0R2MUdpaU9XMFhKRy1QN2xuTXk2VXdiX3Z2cmFMZ0JxMlZaM1RoS3gyTnMwaWE4RmVZVFlBNkhBMF9rUERLU0I3UVNv?oc=5" target="_blank">FDA Issues New Guidance for Submitting Patent Information for Listing in the “Orange Book”</a>  <font color="#6f6f6f">JDSupra</font>

FDA releases draft guidance to accelerate gene therapy development
BioProcess Internationalgeneral

FDA releases draft guidance to accelerate gene therapy development

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQelNCZEtKWEhVY1FnNWVKVkloZjEzYjlKakhzRXdxNE5fZ291U29qMFU3bVNMWDhrbFAzb2pHX0w2QVYyVlRoUEJqTXhmOUtKb3p3emk5WHV6WklFc2ZpVF9DSFdyUzR4WkNNMnY3MU1YaXhqRjVzUFR3ZHlfbVhaTlZWankwaUFldll1dHVFOFlIQkVjanpnbXBiQWZ1ZVlHcjhIRGJZeGhSU0Z2Nnc?oc=5" target="_blank">FDA releases draft guidance to accelerate gene therapy development</a>  <font color="#6f6f6f">BioProcess International</font>

FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies
Inside Precision Medicinegeneral

FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQZXZPOE5GYU5PZ2Z4Uk43N1hzZDJHbmNSU1hJTlpuN1hhZGROMk5mU3NZS1hUaVZXWVFfLVhmeWI5emZWSzJHYmRfUnd2bVVHbEs1dnhud0R0SjN1VlFxNlluWnpRRGZSX1J5MG5nNTNrMzg4eG1CY0FkazlnU3A5cDJjVE5qUVpzYlo5XzJickJ4TUlWSFBoZm1oeWdkUExCM0VIcGNyYkFTUDE4eFhTTzRpSEpBRVp6SkRZZnB3bzlIZUUtV1ozYTBkTTQ5SjhmM2tOMlBlNkJIZWhTTkxlTTlNVUcxRlFvSVBNakN6SUhhYjRt?oc=5" target="_blank">FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies</a>  <font color="#6f6f6f">Inside Precision Medicine</font>

FDA Issues Draft Guidance for Responses to Form 483 Drug CGMP Inspections
Akin Gump Strauss Hauer & Feld LLPgeneral

FDA Issues Draft Guidance for Responses to Form 483 Drug CGMP Inspections

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNNW5NMDZJT2J1M1BZQ1dCWWhidFFNWmVud1c4Mm5fTDNxZjk0T2xsRUxMRkZVSnJrQTgycjBOeWRhZlpoSnlmRjhMb0ZDejFTZDJkQ0tjUFJ5NmN0d0Y2U2VKOEwxREg3S2hPTmlpUDRMVXlTeXBHazcwRGtiWUdZTmRWWVcyZ0ZOMF9xamNHeVJhQW1kUnFMSm9pZWl0VC1ucmFMaWJ5UzZqOWxtTUp0R0JKakFiMV8tSHd6WDVMMW5hVEd1QkE?oc=5" target="_blank">FDA Issues Draft Guidance for Responses to Form 483 Drug CGMP Inspections</a>  <font color="#6f6f6f">Akin Gump Strauss Hauer & Feld LLP</font>

FDA Issues Revised Draft Guidance for Control of Listeria monocytogenes in Ready-to-Eat Foods
Hogan Lovells Cadwaladergeneral

FDA Issues Revised Draft Guidance for Control of Listeria monocytogenes in Ready-to-Eat Foods

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPTlduVkFWNHBzX3JCeWlHOE1ITDFaYmtfUC1xNjVZdjFnMGU3alZ3N3JhZzh1Z3ZOUlJRX2VSVVF1U0hOMGExenFpeXhLYVpHcDYwNjhfV3ZSb0E4a0dkMXg2NFZ3eG4wRVJ1YWxoTFZ4RmxfcDAyTDZwZzBoY1Q2azB0U3E3Q2NrSGIzcGI5aFJxQ0hwT3BsS3BVeUVEcHliQXNYYTRrTmJydVZKdy1WS3NTY1pkMVJpanhkaHIySlMtQjJzUDI1Mg?oc=5" target="_blank">FDA Issues Revised Draft Guidance for Control of Listeria monocytogenes in Ready-to-Eat Foods</a>  <font color="#6f6f6f">Hogan Lovells Cadwalader</font>

FDA issues guidance on responding to Form 483 observations for CGMP drug inspections
www.hlc.comgeneral

FDA issues guidance on responding to Form 483 observations for CGMP drug inspections

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE5VaHJNOTVRZmtNNk9MREE1VWtnX0N4dTQxY3BfR0lmaXBCSEJlcnp5ek1uZ242R1ZYc2NhaTI2S0dYOEkwYi1UdzkxcUFqazFpbGF0bTFpZXNBeHlmdkVNSmw1dVA3NmlhVzd0ZjA5NUhLXzk4SU5vZ1Z2WHE?oc=5" target="_blank">FDA issues guidance on responding to Form 483 observations for CGMP drug inspections</a>  <font color="#6f6f6f">www.hlc.com</font>

FDA Issues Draft Guidance to Advance Bayesian Methods in Clinical Trials
Applied Clinical Trialsgeneral

FDA Issues Draft Guidance to Advance Bayesian Methods in Clinical Trials

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPUmtxNmxTcldsdWFRQWhBR0h3LXhMWmdQdjg1dXlyV2RwVG9wZ3BtN284UklzdVlIV2NlYVhCTldNdlFQTk10ekxwSUp5V0tfU2Rqa29WN0NacHg1ZEh2TTJveVpEaEtVNzNqR3pzLTZTY0pWZXJtNXozQWlucUFlZ2p2T1VQX1VpWkNLcmt1WkdWUC1hVFZPMkFXNzZoTHpaYklYZGlVWkZjS2ktZ3N0aVBfTDVOQQ?oc=5" target="_blank">FDA Issues Draft Guidance to Advance Bayesian Methods in Clinical Trials</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

FDA Issues Draft Guidance for Gene Therapy Genome Editing Safety
Clinical Lab Productsgeneral

FDA Issues Draft Guidance for Gene Therapy Genome Editing Safety

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOM0k5eExVVDdXSzdZeVhiTG9NSjc3VUpnYjB6eXdmMUJaOU9meFZFaDNxNldHY0wtTWRHMTQxVGlBR0gzemVCN29EbXdqX3FXN2tjcjEyem9qRnNIMUpUbC1SbHRzeXctM1pjLTZOeFBNQ3pQejI5cmE4NWdfbThlaVBieFNTZFNmVFlLT2ttbm9YWHExN3FXUG5CZVNOdVlXcm9wWXoyWXhkbVlmb0ZMR2RR?oc=5" target="_blank">FDA Issues Draft Guidance for Gene Therapy Genome Editing Safety</a>  <font color="#6f6f6f">Clinical Lab Products</font>

FDA Issues Draft Guidance Clarifying Three-Year New Clinical Investigation Exclusivity | Advisories
Arnold & Portergeneral

FDA Issues Draft Guidance Clarifying Three-Year New Clinical Investigation Exclusivity | Advisories

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPM2c0T0RKNEV6dmJvenFKSzNrYm1CMXBZWS10NGJoUmM2VXlCMzFQOGRNTjBRVHVqazJzel9jQ0ZCOFRjbmV2cjMxYkl3S1VMS25GOEd0UENxVHluT3lscEo4M0NpUUZZRGdyMXR0NUNtRElRZEdOMzJnZ2Jiem16YXN5R2QyNkVRbVBNZ2k5Tm9MY1U?oc=5" target="_blank">FDA Issues Draft Guidance Clarifying Three-Year New Clinical Investigation Exclusivity | Advisories</a>  <font color="#6f6f6f">Arnold & Porter</font>

FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies
Psychedelic Alphageneral

FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxObk9VckF5M2hodjFQT3RGWGVZT08xbW1CTnJiSXlQUHI3aGl5QzA4MWJ5RWQ1bkxxcVBMTmt2SGZtOHB5b2RaakJ5OXJ4REtYdmpkZXNyT2tfc1BwVTZaV2YzVmRvdTBOMTZYQUcweUFtdXRUWjRlLWVQSUd5SkFIQ2R6aGZ0SUx5UktRT2RyRDhxcXZzcE85NUs5bnBROXgtN2NCd1BRNERCSVlLb29JSjhBZ29PSG5BR1VKdmo4R21hWnNEVDNmU0d4Q2NXNE1VUG4tUV85SQ?oc=5" target="_blank">FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies</a>  <font color="#6f6f6f">Psychedelic Alpha</font>

FDA Issues Draft Guidance on MRD and CR End Points in Multiple Myeloma
Targeted Oncologygeneral

FDA Issues Draft Guidance on MRD and CR End Points in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPV3NQTHRraVlrUXZFLS1RcmJ0Y0M0bUE1clhpYmszb3dtbjh1WnBWdVQxaHBrS0hVeXdyWk9YN1RyZk9va3RUTVhTNG8waFNBdG03cFQyWkdhTmZLOTRhemxBUko5YlE1SWNoSElMeE41bE1pdGlVTFFEeUFkcGFmUEdDVGNSSTBPTnhkbnJVbW80WGZOaDdRNEkyd1lwalRzaGR6b0h3?oc=5" target="_blank">FDA Issues Draft Guidance on MRD and CR End Points in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

FDA issues final PDUFA meeting guidance, expands use of written responses
Drug Discovery & Developmentgeneral

FDA issues final PDUFA meeting guidance, expands use of written responses

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPSlg1SjZiN00tWG1Md1BXQlRXeUpuZDV3UVUzckxQZkFiVThENVV2TDlmcW9hNlQ0bWc2emR1ZWFza0RIdUpaUzFLT0hkTE1IS1dtWU50eVVsOUNiTFpMWEFZS0QyY1R1TTh3SG1QLXNZeHRUUUlha3RWb1VSMGc1LVV0cTlZa2ZUdkpDVW90Z0h1VktaQjlQSTFUMWdQcFBqbVlIYXppTU1KWTFxOXc?oc=5" target="_blank">FDA issues final PDUFA meeting guidance, expands use of written responses</a>  <font color="#6f6f6f">Drug Discovery & Development</font>

FDA issues draft guidance to reduce 6-month nonhuman primate testing for monoclonal antibodies
DVM 360general

FDA issues draft guidance to reduce 6-month nonhuman primate testing for monoclonal antibodies

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQS3VnQm5xNDRKM3Mwc3lqUWJmWHQzbGNpU0VQZTlQMUQ5MFgtN0VzRm9adnQwM01CRUIzNDVRLVZpNXhkZnlZb2VmQlJMeW15SlBnMDQ2MV9TUjdfUFlsc2xidjYzZG9rYVg0ZjFMcGlubVdOZm54a0lsekoxVkN0ZnRNeGY3bl9yajZCNDZ0QXVfN3ZKRERIODFRVUg3d1czb0gwWkwyOGxNS2o0amZ2S1lodE84dkwzbTEyTU1vUVY2Zw?oc=5" target="_blank">FDA issues draft guidance to reduce 6-month nonhuman primate testing for monoclonal antibodies</a>  <font color="#6f6f6f">DVM 360</font>

Key FDA Updates: Substantial Evidence, Gene Therapy Development and AI-Enabled Early-Phase Clinical Trials
McGuireWoodstech

Key FDA Updates: Substantial Evidence, Gene Therapy Development and AI-Enabled Early-Phase Clinical Trials

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxNenlvM0tDc2hyOUtETDljUGh5OXgwZXhTYWNRa0xBMUxIZzFUZzJabm9LVHVEYi1DMHhFYjhSVUpUVU1iS2pMa1Z4dkRvOUlLRHRSeDBDZmJVSmxWTEpPeE93bGZqR3ByM3dwMG4zRWJOcGNCcTlLT3pfSkxCektlNUxVODRodGRuMldaLUJvWUpvVk1Obm51WXhoaFYxVWljaEtlc01Jblh3ZGtZOFFJeEpOLXhERmkxZDBmdWs1WGVsdGNKZ0VkblJ5R0lIUkt0N0ItYTlpaVFSd3NGVzB2ckVLX1NmMzE4OVBuWDJUc1FSZmM3cktIZA?oc=5" target="_blank">Key FDA Updates: Substantial Evidence, Gene Therapy Development and AI-Enabled Early-Phase Clinical Trials</a>  <font color="#6f6f6f">McGuireWoods</font>

FDA issues 3-year exclusivity draft guidance clarifying requirements to obtain exclusivity and providing model language for requesting exclusivity
www.hlc.comtech

FDA issues 3-year exclusivity draft guidance clarifying requirements to obtain exclusivity and providing model language for requesting exclusivity

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNSzFaQWV6cDljdEo5Yk1hNm1RMVpMS0JUdVlDazUwU3FBU0J6Q2V6TGswRUhneTluU3MtbXRwVFNteHBGY1JTVnQ0TEtTTXRLQ01QcDdSaVJQWk5pOTdIZVdpM1ZYajFtd2lTdHJLaGctTHFjWmU0QXA3Y1JUZjJEa3pjX1dxdw?oc=5" target="_blank">FDA issues 3-year exclusivity draft guidance clarifying requirements to obtain exclusivity and providing model language for requesting exclusivity</a>  <font color="#6f6f6f">www.hlc.com</font>

FDA Policy Tracker 2026: FDA taps prior knowledge to expedite cell and gene therapy development
BioSpacegeneral

FDA Policy Tracker 2026: FDA taps prior knowledge to expedite cell and gene therapy development

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExtVEdya3I4QUNjLUZHOVdFSnJhdHUyQUgzRDdPc2RtLUJiMkhCeFpFZ0w3Sm9ValpZRHdHNGRNZTFDeXlSVTI1YTFBUG1ZVlowSzFrSnBWclpTX2pDS1dFc05sNFpydnI2Tk44SGhpOHFFOGZ6RGwxeUY0X2lSSkZLN3Y5M29YeFN3UmpwNUFqX0tvUDQ1dA?oc=5" target="_blank">FDA Policy Tracker 2026: FDA taps prior knowledge to expedite cell and gene therapy development</a>  <font color="#6f6f6f">BioSpace</font>

FDA Publishes Draft Guidance on Three-Year New Clinical Investigation Exclusivity – As Prescribed
Morgan Lewisgeneral

FDA Publishes Draft Guidance on Three-Year New Clinical Investigation Exclusivity – As Prescribed

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPNVNUNld0Z2F3c1gzRlJ4Ync5ak1BM29RR1lKOG4yZXhpcUxTWXZZd3BOTW93NUhrTXB0WnFmTkxRYk1EWU82MTJaTlFDejlfdC1LaTlRaU5PcDRid1pvdk1MVnRCbW1SVGx5d3JNcGNZZmhEc240cDNzSlVVaWhhUnpXYXR4WWQ4eFd1OTB1a2xCejRNZFVlZHJEcWZwcC1iU2MzM2JLRk5wcW5NRjBPX2RKQVRQNmdra0dqX2N1Mnh1OU9CU0JMNUpFQTV5bnN2Mnc?oc=5" target="_blank">FDA Publishes Draft Guidance on Three-Year New Clinical Investigation Exclusivity – As Prescribed</a>  <font color="#6f6f6f">Morgan Lewis</font>

"FDA Issues Draft Guidance" — Live Google News Trends & Headlines